TransMedics Group, Inc. january 10, 2025 Please complete the form below to contact Kaplan Fox regarding the TransMedics Group, Inc. Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Pamela MayerPMayer@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox & Kilsheimer LLP is Investigating TransMedics Group, Inc. (TMDX) for Potential Securities Law Violations Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a TransMedics investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. On January 10, 2025, Scorpion Capital published a short report entitled, “Walk Like An Egyptian: A ‘Mafia-Style’ Extortion, Racketeering, And Organ Trafficking Scheme Masquerading And A Medical Device Company – Fueled By Kickbacks, Billing Fraud, Unreported Device Failures, And Off-Label Misuse On A Vast Scale; Precipitating A Customer Exodus And Rapidly Unfolding Death Spiral. Target Price: $0” (“the Report”). The Report alleges, among other things, fraudulent billing schemes, off-label misuse of its devices, and reliance on kickbacks to drive sales. The Report also alleges that the Company may be under regulatory scrutiny by the U.S. Department of Justice, Internal Revenue Service, and state attorneys general for Medicare fraud linked to organ acquisition costs. On this news, the price of TransMedics stock fell by $3.74, or 5.16%, to close at $68.81 on January 10, 2025. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: Pamela A. MayerKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003pmayer@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704lking@kaplanfox.com Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us AstraZeneca PLC See the Case TransMedics Group, Inc. See the Case Nextracker Inc. See the Case Revance Therapeutics, Inc. See the Case Carvana Co. See the Case MGP Ingredients, Inc. See the Case Dave & Busters Entertainment, Inc. See the Case Celsius Holdings, Inc. See the Case Dentsply Sirona Inc. See the Case Western Asset Macro Opportunities Fund See the Case Franklin Resources, Inc. See the Case Customers Bancorp, Inc. See the Case
